Mankind Pharma files papers for $700 million plus IPO; Largest ever in sector | The Financial Express

Mankind Pharma files papers for $700 million plus IPO; Largest ever in sector

Mankind Pharma files Papers for $700 million plus IPO: The company will not receive any proceeds from the offer and all the proceeds will be received by the selling shareholders, as per the DRHP.

Mankind Pharma files papers for $700 million plus IPO; Largest ever in sector
Mankind Pharma files for IPO, could be one of largest ever in pharma (File)

Mankind Pharma Files For Initial Public Offering: Mankind Pharma on Friday filed preliminary papers with the markets regulator Securities and Exchange Board of India (SEBI) to raise funds upwards of $700 million through an Initial Public Offering (IPO).

Reportedly, this is one of the biggest ever filing attempted by any player in the segment. Gland Pharma was the previous record holder which launched an $869 million IPO in November 2020.

The company’s IPO comprises an offer for the sale of 4,00,58,884 equity shares by selling shareholders, including promoters and existing investors, according to the Draft Red Herring Prospectus (DRHP).

Meanwhile, the offer for sale comprises of up to 37,05,443 equity shares by Ramesh Juneja, up to 35,05,149 equity shares by Rajeev Juneja, and up to 28,04,119 equity shares by Sheetal Arora (collectively the promoter selling shareholders).

Further, up to 1,74,05,559 equity shares by Cairnhill CIPEF, up to 26,23,863 equity shares by Cairnhill CGPE, up to 99,64,711 equity shares by Beige Limited and up to 50,000 equity shares by Link Investment Trust (collectively the investor selling shareholders). All these are part of Offer For Sale (OFS).

At present, the company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.

The Company is focused on the domestic market, as a result of which its revenue from operations in India contributed to 97.60% of its total revenue from operations for the Financial Year 2022, which was one of the highest among peers identified by IQVIA.

The company will not receive any proceeds from the offer and all the proceeds will be received by the selling shareholders, as per the DRHP.

Kotak Mahindra Capital Company, Axis Capital, IIFL Securities, Jefferies India and J P Morgan India are the book running lead managers to the issue. Moreover, the equity shares of the company are proposed to be listed on the BSE and National Stock Exchange of India.

ALSO READ | Mankind Pharma partners with NOTTO to create awareness about organ donation

Get live Share Market updates and latest India News and business news on Financial Express. Download Financial Express App for latest business news.